No Good Day at Array (ARRY)

Posted in pre-market 
September 4th, 2009

Array BioPharma Inc. (NASDAQ: ARRY) was whacked after the emerging drug and biotech player said its experimental rheumatoid arthritis treatment study failed to meet its endpoints and was not more effective than the placebo in reducing symptoms.  At 9:05 AM EST we have already seen 350,000 shares trade hands versus an average volume of about 220,000.  The drop is down about 28.5% at $2.74 after closing at $3.78 yesterday.  This one is now a fraction of its $8.83 high over the last year. -JON OGG

Comments are closed

-->